Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08634404 plus chemotherapy versus nivolumab plus chemotherapy in previously untreated advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma
MOH_2026-03-18_015720Phase 3Not yet recruiting
- Sponsor
- Pfizer
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of PF-08634404 and nivolumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) (3 arms), sponsored by Pfizer. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
PF-08634404nivolumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on MOH_2026-03-18_015720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-03-18_015720.